GYN | Metformin for the Treatment of Endometrial Hyperplasia

STUDY BRIEF | Trial to assess the impact of metformin for the treatment of simple or complex endometrial hyperplasia without atypia. Metformin may offer an alternative agent for treatment of endometrial hyperplasia without causing significant side effects common to progesterone-based treatment.

Endometrial hyperplasia occurs when the endometrium, the lining of the uterus, becomes too thick. It is not cancer, but in some cases, it can lead to cancer of the uterus. ACOG Patient Information

Principal Investigator
V. Bae-Jump; E. Ko

Recruitment Length
10/1/2012; 12/31/2013

Participation Details
2 clinic visits in 3 months.

Compensation available?

Qualifiers for the study
Age 18-75; Diagnosis of endometrial hyperplasia without atypia; normal serum creatinine and liver function tests; no contraindication to metformin.

Exclusion Criteria
Currently taking metformin or metformin use in the past 6 months; current insulin use; liver or kidney dysfunction; history of alcoholism; history B12 deficiency; pregnant.

Study Contact Person Name, Number: Mark Bozymski Pager 919-216-2481, Office 919-966-4432

IRB Approval Number

Filed under: